Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, China.
Department of Obstetrics and Gynecology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, China.
Mol Ther. 2021 Jun 2;29(6):1958-1969. doi: 10.1016/j.ymthe.2021.04.029. Epub 2021 Apr 29.
Multiple studies have confirmed that programmed cell death 1/programmed cell death ligand-1 (PD-1/PD-L1) and immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 play pivotal roles in the treatment of numerous tumors. Patients suffering from cancer are provided hope in the form of immunotherapy. In this review, we discuss the finding that high PD-L1 expression is associated with poor clinical outcomes in prostate cancer patients. Some molecules exert their antitumor effects by downregulating PD-L1 expression in prostate cancer. Additionally, we discuss and summarize the important roles played by anti-PD-1/PD-L1 immunotherapy and its combination with other drugs, including chemotherapy and vaccines, in the treatment of prostate cancer.
多项研究证实，程序性细胞死亡蛋白 1/程序性细胞死亡配体 1（PD-1/PD-L1）和针对 PD-1/PD-L1 的免疫检查点抑制剂（ICIs）在治疗多种肿瘤中发挥着关键作用。癌症患者通过免疫疗法获得了希望。在这篇综述中，我们讨论了 PD-L1 高表达与前列腺癌患者临床结局不良相关的发现。一些分子通过下调前列腺癌细胞中的 PD-L1 表达发挥抗肿瘤作用。此外，我们还讨论并总结了抗 PD-1/PD-L1 免疫疗法及其与其他药物（包括化疗药物和疫苗）联合应用在前列腺癌治疗中的重要作用。
